Advent Technologies (ADN) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
22 Oct, 2025Opening remarks and agenda
Meeting convened at 9:00 A.M. with a welcome from the CEO and introduction of the Inspector of Elections.
Only registered stockholders were eligible to vote; notice of meeting mailed to shareholders of record as of September 19, 2025.
Agenda included election of directors, ratification of auditors, approval of stock issuance, incentive plan amendment, executive compensation, and other business.
Shareholder proposals
Election of three Class II directors to serve until the 2028 annual meeting.
Ratification of M&K CPAS, PLLC as independent registered public accounting firm for fiscal year ending December 31, 2025.
Approval of potential issuance and sale of 20% or more of common stock, up to $52 million, to Hudson Global Ventures LLC.
Amendment to the 2021 Incentive Plan to increase issuable shares and provide for annual increases through 2046.
Advisory vote on executive compensation and on the frequency of such votes.
Consideration of other business as may properly come before the meeting.
Overview of voting outcomes
Quorum established with 39.73% of outstanding shares represented.
Mark Tillenfriend, Seth Lukash, and Joseph Silia elected as Class II directors until 2028.
Ratification of M&K CPAS, PLLC as auditor approved by majority vote.
Approval granted for potential issuance and sale of 20% or more of common stock to Hudson Global Ventures LLC.
Amendment to 2021 Incentive Plan approved, increasing issuable shares and setting annual increase provisions.
Executive compensation approved by advisory vote.
Advisory vote on executive compensation to be held every three years, as approved by majority.
Latest events from Advent Technologies
- Q4 revenue and cash fell as cost cuts and partnerships drove a shift to licensing and MEA focus.ADN
Q4 202323 Jan 2026 - Director and auditor ratified; other business matters not approved at the meeting.ADN
AGM 202410 Jan 2026 - Shareholders will vote on director elections, auditor ratification, stock issuance, and incentive plan changes.ADN
Proxy Filing1 Dec 2025 - Annual meeting to elect a director, ratify auditor, and address other business, all board-recommended.ADN
Proxy Filing1 Dec 2025 - Seeks up to $52M equity funding amid losses and going concern risk, leveraging HT-PEM tech and partnerships.ADN
Registration Filing28 Nov 2025 - Liquidity crisis persists despite improved net income; delisted, high debt, and major legal risks remain.ADN
Q3 202517 Nov 2025 - Severe liquidity challenges, legal settlements, and a major EU grant defined the quarter.ADN
Q2 202512 Aug 2025 - Severe liquidity challenges persist despite cost cuts and a major EU grant, with going concern risks looming.ADN
Q1 202530 Jun 2025 - Revenue up 113% year-over-year, but severe liquidity risk and going concern doubts persist.ADN
Q4 202530 Jun 2025